Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Superfibronectin, a multimeric form of fibronectin, increases HIV infection of primary CD4+ T lymphocytes.

J Immunol. 2000 Mar 15;164(6):3236-45. Unique Identifier : AIDSLINE MED/20171526
Tellier MC; Greco G; Klotman M; Mosoian A; Cara A; Arap W; Ruoslahti E; Pasqualini R; Schnapp LM; Divisions of Pulmonary and Critical Care Medicine and Infectious; Disease, Mount Sinai School of Medicine, New York, NY 10029, USA.


Abstract: The ability of viruses and bacteria to interact with the extracellular matrix plays an important role in their infectivity and pathogenicity. Fibronectin is a major component of the extracellular matrix in lymph node tissue, the main site of HIV deposition and replication during the chronic phase of infection. Therefore, we asked whether matrix fibronectin (FN) could affect the ability of HIV to infect lymphocytes. To study the role of matrix FN on HIV infection, we used superfibronectin (sFN), a multimeric form of FN that closely resembles in vivo matrix FN. In this study we show that HIV-1IIIB efficiently binds to multimeric fibronectin (sFN) and that HIV infection of primary CD4+ lymphocytes is enhanced by >1 order of magnitude in the presence of sFN. This increase appears to be due to increased adhesion of viral particles to the cell surface in the presence of sFN, followed by internalization of virus. Enzymatic removal of cell surface proteoglycans inhibited the adhesion of HIV-1IIIB/sFN complexes to lymphocytes. In contrast, Abs to integrins had no effect on binding of HIV-1IIIB/sFN complexes to lymphocytes. The III1-C peptide alone also bound HIV-1IIIB efficiently and enhanced HIV infection, although not as effectively as sFN. HIV-1IIIB gp120 envelope protein binds to the III1-C region of sFN and may be important in the interaction of virus with matrix FN. We conclude that HIV-1IIIB specifically interacts with the III1-C region within matrix FN, and that this interaction may play a role in facilitating HIV infection in vivo, particularly in lymph node tissue.


Keywords: JOURNAL ARTICLE Animal Binding, Competitive Biopolymers/*CHEMISTRY/*IMMUNOLOGY/METABOLISM Cell Membrane/METABOLISM/VIROLOGY Comparative Study CD4-Positive T-Lymphocytes/*IMMUNOLOGY/METABOLISM/*VIROLOGY Epitopes/CHEMISTRY/METABOLISM Fibronectins/*CHEMISTRY/*IMMUNOLOGY/METABOLISM Heparitin Sulfate/METABOLISM Human HIV Envelope Protein gp120/PHYSIOLOGY HIV Long Terminal Repeat/IMMUNOLOGY HIV-1/GENETICS/*IMMUNOLOGY/METABOLISM Integrins/PHYSIOLOGY Jurkat Cells Lymph Nodes/IMMUNOLOGY/METABOLISM/VIROLOGY Lymphocyte Transformation Proteoglycans/PHYSIOLOGY Rats Receptors, Virus/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Up-Regulation (Physiology)/IMMUNOLOGY Virion/METABOLISM

KWDjournalarticleanimalbinding,competitivebiopolymers/KWDchemistry/KWDimmunology/metabolismcellmembrane/metabolism/virologycomparativestudycd4-positivet-lymphocytes/KWDimmunology/metabolism/KWDvirologyepitopes/chemistry/metabolismfibronectins/KWDchemistry/KWDimmunology/metabolismheparitinsulfate/metabolismhumanhivenvelopeproteingp120/physiologyhivlongterminalrepeat/immunologyhiv-1/genetics/KWDimmunology/metabolismintegrins/physiologyjurkatcellslymphnodes/immunology/metabolism/virologylymphocytetransformationproteoglycans/physiologyratsreceptors,virus/metabolismsupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDup-regulation(physiology)/immunologyvirion/metabolism
000630
A0061908


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .